The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s (NYSE:BMY) Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of cancer, with high long-term survival rates, particularly when detected early.

• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?

Hodgkin lymphoma (HL) is a cancer in which multinucleated Reed–Sternberg cells (RS cells) are present in the lymph nodes.

The approval covers nivolumab with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage ...